Glass Pharms, a UK-based cultivator of medical cannabis flower, has announced a new supply agreement with Integro Clinic & IPS Pharmacy. The agreement will provide Integro and Medicann clinics, as well as other UK clinics, with a premium range of Glass Pharms branded CBPMs made with domestically grown flower from the Glass Pharms facility.
This new agreement follows positive patient feedback from IPS prescribing Glass Pharms derived CBPMs earlier this year. The success of these products has led to the expansion of the range, with five new products now available based on cultivars produced by Glass Pharms.
James Duckenfield, CEO of Glass Pharms, expressed his delight in the direct supply agreement, stating that IPS’ positive patient feedback gave them confidence to expand the range. He also looks forward to offering new prescribing options that will broaden the range.
Tony Dutta, CEO of IPS Pharma, also shared his support for the UK-based supply chain, stating that it provides patients with assurance of continuity in their prescribing needs. He highlighted Glass Pharms’ high quality standards, including achieving microbial standards without irradiation, as well as their environmentally friendly and patient-focused approach.
Glass Pharms continues to increase production capacities at their 2.4-hectare facility in Wiltshire, which boasts top-notch sustainability credentials and a quality-by-design approach to microbial safety in the production of medical cannabis flower. The UK medical cannabis market has seen steady growth as the supply chain matures and private treatment becomes more affordable, making it an attractive option for patients.
For more information on Glass Pharms and IPS Pharma, please visit their websites at https://glasspharms.com/ and https://ips-pharma.com/, respectively. For media inquiries, please contact Mark Heley at info@glasspharms.com.
